The global Enzalutamide Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Enzalutamide drugs are medications that contain enzalutamide, an androgen receptor inhibitor that works by blocking the effects of androgens (male hormones like testosterone) on cancer cells.

From a downstream perspective, Hospital and Clinic accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Enzalutamide Drugs leading manufacturers including Astellas Pharma, Pfizer, Intas Pharmaceuticals, Beacon pharma, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, Sun Pharma, Zydus, Abbott Laboratories, etc., dominate supply; the top five capture approximately % of global revenue, with Astellas Pharma leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Enzalutamide Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Enzalutamide Drugs Market Report

Report Metric	Details
Report Name	Enzalutamide Drugs Market
Segment by Type	Tablets Capsules
Segment by Application	Hospital and Clinic Retail Pharmacies Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma, Pfizer, Intas Pharmaceuticals, Beacon pharma, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, Sun Pharma, Zydus, Abbott Laboratories, BDR Pharma, Qilu Pharmaceutical, Kelun Pharmaceutical, Yichang Humanwell Pharmaceutical, Jiangsu Hansoh Pharmaceutical, PuraCap Pharmaceuticals, Shenyang Hongqi Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Enzalutamide Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Enzalutamide Drugs Market report?

Ans: The main players in the Enzalutamide Drugs Market are Astellas Pharma, Pfizer, Intas Pharmaceuticals, Beacon pharma, Aprazer Healthcare Pharma, Arechar Healthcare, Glenmark Pharma, Sun Pharma, Zydus, Abbott Laboratories, BDR Pharma, Qilu Pharmaceutical, Kelun Pharmaceutical, Yichang Humanwell Pharmaceutical, Jiangsu Hansoh Pharmaceutical, PuraCap Pharmaceuticals, Shenyang Hongqi Pharmaceutical

What are the Application segmentation covered in the Enzalutamide Drugs Market report?

Ans: The Applications covered in the Enzalutamide Drugs Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Enzalutamide Drugs Market report?

Ans: The Types covered in the Enzalutamide Drugs Market report are Tablets, Capsules

1 Study Coverage

1.1 Introduction to Enzalutamide Drugs: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Enzalutamide Drugs Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Tablets

1.2.3 Capsules

1.3 Market Segmentation by Application

1.3.1 Global Enzalutamide Drugs Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Enzalutamide Drugs Revenue Estimates and Forecasts 2020-2031

2.2 Global Enzalutamide Drugs Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Enzalutamide Drugs Sales Estimates and Forecasts 2020-2031

2.4 Global Enzalutamide Drugs Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Enzalutamide Drugs Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Enzalutamide Drugs Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Tablets Market Size by Manufacturers

3.5.2 Capsules Market Size by Manufacturers

3.6 Global Enzalutamide Drugs Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Enzalutamide Drugs Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Enzalutamide Drugs Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Enzalutamide Drugs Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Enzalutamide Drugs Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Enzalutamide Drugs Sales and Revenue by Type (2020-2031)

6.4 North America Enzalutamide Drugs Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Enzalutamide Drugs Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Enzalutamide Drugs Sales and Revenue by Type (2020-2031)

7.4 Europe Enzalutamide Drugs Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Enzalutamide Drugs Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Enzalutamide Drugs Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Enzalutamide Drugs Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Enzalutamide Drugs Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Enzalutamide Drugs Sales and Revenue by Type (2020-2031)

9.4 Central and South America Enzalutamide Drugs Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Enzalutamide Drugs Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Enzalutamide Drugs Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Enzalutamide Drugs Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Enzalutamide Drugs Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Astellas Pharma

11.1.1 Astellas Pharma Corporation Information

11.1.2 Astellas Pharma Business Overview

11.1.3 Astellas Pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.1.4 Astellas Pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Astellas Pharma Enzalutamide Drugs Sales by Product in 2024

11.1.6 Astellas Pharma Enzalutamide Drugs Sales by Application in 2024

11.1.7 Astellas Pharma Enzalutamide Drugs Sales by Geographic Area in 2024

11.1.8 Astellas Pharma Enzalutamide Drugs SWOT Analysis

11.1.9 Astellas Pharma Recent Developments

11.2 Pfizer

11.2.1 Pfizer Corporation Information

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Enzalutamide Drugs Product Models, Descriptions and Specifications

11.2.4 Pfizer Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Pfizer Enzalutamide Drugs Sales by Product in 2024

11.2.6 Pfizer Enzalutamide Drugs Sales by Application in 2024

11.2.7 Pfizer Enzalutamide Drugs Sales by Geographic Area in 2024

11.2.8 Pfizer Enzalutamide Drugs SWOT Analysis

11.2.9 Pfizer Recent Developments

11.3 Intas Pharmaceuticals

11.3.1 Intas Pharmaceuticals Corporation Information

11.3.2 Intas Pharmaceuticals Business Overview

11.3.3 Intas Pharmaceuticals Enzalutamide Drugs Product Models, Descriptions and Specifications

11.3.4 Intas Pharmaceuticals Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Intas Pharmaceuticals Enzalutamide Drugs Sales by Product in 2024

11.3.6 Intas Pharmaceuticals Enzalutamide Drugs Sales by Application in 2024

11.3.7 Intas Pharmaceuticals Enzalutamide Drugs Sales by Geographic Area in 2024

11.3.8 Intas Pharmaceuticals Enzalutamide Drugs SWOT Analysis

11.3.9 Intas Pharmaceuticals Recent Developments

11.4 Beacon pharma

11.4.1 Beacon pharma Corporation Information

11.4.2 Beacon pharma Business Overview

11.4.3 Beacon pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.4.4 Beacon pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Beacon pharma Enzalutamide Drugs Sales by Product in 2024

11.4.6 Beacon pharma Enzalutamide Drugs Sales by Application in 2024

11.4.7 Beacon pharma Enzalutamide Drugs Sales by Geographic Area in 2024

11.4.8 Beacon pharma Enzalutamide Drugs SWOT Analysis

11.4.9 Beacon pharma Recent Developments

11.5 Aprazer Healthcare Pharma

11.5.1 Aprazer Healthcare Pharma Corporation Information

11.5.2 Aprazer Healthcare Pharma Business Overview

11.5.3 Aprazer Healthcare Pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.5.4 Aprazer Healthcare Pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Aprazer Healthcare Pharma Enzalutamide Drugs Sales by Product in 2024

11.5.6 Aprazer Healthcare Pharma Enzalutamide Drugs Sales by Application in 2024

11.5.7 Aprazer Healthcare Pharma Enzalutamide Drugs Sales by Geographic Area in 2024

11.5.8 Aprazer Healthcare Pharma Enzalutamide Drugs SWOT Analysis

11.5.9 Aprazer Healthcare Pharma Recent Developments

11.6 Arechar Healthcare

11.6.1 Arechar Healthcare Corporation Information

11.6.2 Arechar Healthcare Business Overview

11.6.3 Arechar Healthcare Enzalutamide Drugs Product Models, Descriptions and Specifications

11.6.4 Arechar Healthcare Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Arechar Healthcare Recent Developments

11.7 Glenmark Pharma

11.7.1 Glenmark Pharma Corporation Information

11.7.2 Glenmark Pharma Business Overview

11.7.3 Glenmark Pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.7.4 Glenmark Pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Glenmark Pharma Recent Developments

11.8 Sun Pharma

11.8.1 Sun Pharma Corporation Information

11.8.2 Sun Pharma Business Overview

11.8.3 Sun Pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.8.4 Sun Pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Sun Pharma Recent Developments

11.9 Zydus

11.9.1 Zydus Corporation Information

11.9.2 Zydus Business Overview

11.9.3 Zydus Enzalutamide Drugs Product Models, Descriptions and Specifications

11.9.4 Zydus Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Zydus Recent Developments

11.10 Abbott Laboratories

11.10.1 Abbott Laboratories Corporation Information

11.10.2 Abbott Laboratories Business Overview

11.10.3 Abbott Laboratories Enzalutamide Drugs Product Models, Descriptions and Specifications

11.10.4 Abbott Laboratories Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Abbott Laboratories Recent Developments

11.11 BDR Pharma

11.11.1 BDR Pharma Corporation Information

11.11.2 BDR Pharma Business Overview

11.11.3 BDR Pharma Enzalutamide Drugs Product Models, Descriptions and Specifications

11.11.4 BDR Pharma Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 BDR Pharma Recent Developments

11.12 Qilu Pharmaceutical

11.12.1 Qilu Pharmaceutical Corporation Information

11.12.2 Qilu Pharmaceutical Business Overview

11.12.3 Qilu Pharmaceutical Enzalutamide Drugs Product Models, Descriptions and Specifications

11.12.4 Qilu Pharmaceutical Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.12.5 Qilu Pharmaceutical Recent Developments

11.13 Kelun Pharmaceutical

11.13.1 Kelun Pharmaceutical Corporation Information

11.13.2 Kelun Pharmaceutical Business Overview

11.13.3 Kelun Pharmaceutical Enzalutamide Drugs Product Models, Descriptions and Specifications

11.13.4 Kelun Pharmaceutical Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.13.5 Kelun Pharmaceutical Recent Developments

11.14 Yichang Humanwell Pharmaceutical

11.14.1 Yichang Humanwell Pharmaceutical Corporation Information

11.14.2 Yichang Humanwell Pharmaceutical Business Overview

11.14.3 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Product Models, Descriptions and Specifications

11.14.4 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.14.5 Yichang Humanwell Pharmaceutical Recent Developments

11.15 Jiangsu Hansoh Pharmaceutical

11.15.1 Jiangsu Hansoh Pharmaceutical Corporation Information

11.15.2 Jiangsu Hansoh Pharmaceutical Business Overview

11.15.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Product Models, Descriptions and Specifications

11.15.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.15.5 Jiangsu Hansoh Pharmaceutical Recent Developments

11.16 PuraCap Pharmaceuticals

11.16.1 PuraCap Pharmaceuticals Corporation Information

11.16.2 PuraCap Pharmaceuticals Business Overview

11.16.3 PuraCap Pharmaceuticals Enzalutamide Drugs Product Models, Descriptions and Specifications

11.16.4 PuraCap Pharmaceuticals Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.16.5 PuraCap Pharmaceuticals Recent Developments

11.17 Shenyang Hongqi Pharmaceutical

11.17.1 Shenyang Hongqi Pharmaceutical Corporation Information

11.17.2 Shenyang Hongqi Pharmaceutical Business Overview

11.17.3 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Product Models, Descriptions and Specifications

11.17.4 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.17.5 Shenyang Hongqi Pharmaceutical Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Enzalutamide Drugs Industry Chain

12.2 Enzalutamide Drugs Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Enzalutamide Drugs Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Enzalutamide Drugs Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Enzalutamide Drugs Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Enzalutamide Drugs Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Intas Pharmaceuticals

Yichang Humanwell Pharmaceutical

Jiangsu Hansoh Pharmaceutical

Puracap Pharmaceuticals

Shenyang Hongqi Pharmaceutical

Aprazer Healthcare Pharma

Arechar Healthcare

List of Tables

Table 1. Global Enzalutamide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Enzalutamide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Enzalutamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Enzalutamide Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Enzalutamide Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Enzalutamide Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global Enzalutamide Drugs Sales by Region (2020-2025) & (K Units)

Table 8. Global Enzalutamide Drugs Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Enzalutamide Drugs Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global Enzalutamide Drugs Sales Share by Manufacturers (2020-2025)

Table 12. Global Enzalutamide Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Enzalutamide Drugs Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Enzalutamide Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Enzalutamide Drugs as of 2024)

Table 16. Global Enzalutamide Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Enzalutamide Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Enzalutamide Drugs Manufacturing Base and Headquarters

Table 19. Global Enzalutamide Drugs Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Enzalutamide Drugs Sales by Type (2020-2025) & (K Units)

Table 23. Global Enzalutamide Drugs Sales by Type (2026-2031) & (K Units)

Table 24. Global Enzalutamide Drugs Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Enzalutamide Drugs Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Enzalutamide Drugs ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Enzalutamide Drugs Sales by Application (2020-2025) & (K Units)

Table 29. Global Enzalutamide Drugs Sales by Application (2026-2031) & (K Units)

Table 30. Enzalutamide Drugs High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Enzalutamide Drugs Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Enzalutamide Drugs Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Enzalutamide Drugs ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Enzalutamide Drugs Growth Accelerators and Market Barriers

Table 37. North America Enzalutamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Enzalutamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Enzalutamide Drugs Growth Accelerators and Market Barriers

Table 40. Europe Enzalutamide Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Enzalutamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Enzalutamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Enzalutamide Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Enzalutamide Drugs Growth Accelerators and Market Barriers

Table 45. Southeast Asia Enzalutamide Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Enzalutamide Drugs Investment Opportunities and Key Challenges

Table 47. Central and South America Enzalutamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Enzalutamide Drugs Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Enzalutamide Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Astellas Pharma Corporation Information

Table 51. Astellas Pharma Description and Major Businesses

Table 52. Astellas Pharma Product Models, Descriptions and Specifications

Table 53. Astellas Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Astellas Pharma Sales Value Proportion by Product in 2024

Table 55. Astellas Pharma Sales Value Proportion by Application in 2024

Table 56. Astellas Pharma Sales Value Proportion by Geographic Area in 2024

Table 57. Astellas Pharma Enzalutamide Drugs SWOT Analysis

Table 58. Astellas Pharma Recent Developments

Table 59. Pfizer Corporation Information

Table 60. Pfizer Description and Major Businesses

Table 61. Pfizer Product Models, Descriptions and Specifications

Table 62. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Pfizer Sales Value Proportion by Product in 2024

Table 64. Pfizer Sales Value Proportion by Application in 2024

Table 65. Pfizer Sales Value Proportion by Geographic Area in 2024

Table 66. Pfizer Enzalutamide Drugs SWOT Analysis

Table 67. Pfizer Recent Developments

Table 68. Intas Pharmaceuticals Corporation Information

Table 69. Intas Pharmaceuticals Description and Major Businesses

Table 70. Intas Pharmaceuticals Product Models, Descriptions and Specifications

Table 71. Intas Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Intas Pharmaceuticals Sales Value Proportion by Product in 2024

Table 73. Intas Pharmaceuticals Sales Value Proportion by Application in 2024

Table 74. Intas Pharmaceuticals Sales Value Proportion by Geographic Area in 2024

Table 75. Intas Pharmaceuticals Enzalutamide Drugs SWOT Analysis

Table 76. Intas Pharmaceuticals Recent Developments

Table 77. Beacon pharma Corporation Information

Table 78. Beacon pharma Description and Major Businesses

Table 79. Beacon pharma Product Models, Descriptions and Specifications

Table 80. Beacon pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Beacon pharma Sales Value Proportion by Product in 2024

Table 82. Beacon pharma Sales Value Proportion by Application in 2024

Table 83. Beacon pharma Sales Value Proportion by Geographic Area in 2024

Table 84. Beacon pharma Enzalutamide Drugs SWOT Analysis

Table 85. Beacon pharma Recent Developments

Table 86. Aprazer Healthcare Pharma Corporation Information

Table 87. Aprazer Healthcare Pharma Description and Major Businesses

Table 88. Aprazer Healthcare Pharma Product Models, Descriptions and Specifications

Table 89. Aprazer Healthcare Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Aprazer Healthcare Pharma Sales Value Proportion by Product in 2024

Table 91. Aprazer Healthcare Pharma Sales Value Proportion by Application in 2024

Table 92. Aprazer Healthcare Pharma Sales Value Proportion by Geographic Area in 2024

Table 93. Aprazer Healthcare Pharma Enzalutamide Drugs SWOT Analysis

Table 94. Aprazer Healthcare Pharma Recent Developments

Table 95. Arechar Healthcare Corporation Information

Table 96. Arechar Healthcare Description and Major Businesses

Table 97. Arechar Healthcare Product Models, Descriptions and Specifications

Table 98. Arechar Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Arechar Healthcare Recent Developments

Table 100. Glenmark Pharma Corporation Information

Table 101. Glenmark Pharma Description and Major Businesses

Table 102. Glenmark Pharma Product Models, Descriptions and Specifications

Table 103. Glenmark Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Glenmark Pharma Recent Developments

Table 105. Sun Pharma Corporation Information

Table 106. Sun Pharma Description and Major Businesses

Table 107. Sun Pharma Product Models, Descriptions and Specifications

Table 108. Sun Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Sun Pharma Recent Developments

Table 110. Zydus Corporation Information

Table 111. Zydus Description and Major Businesses

Table 112. Zydus Product Models, Descriptions and Specifications

Table 113. Zydus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Zydus Recent Developments

Table 115. Abbott Laboratories Corporation Information

Table 116. Abbott Laboratories Description and Major Businesses

Table 117. Abbott Laboratories Product Models, Descriptions and Specifications

Table 118. Abbott Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Abbott Laboratories Recent Developments

Table 120. BDR Pharma Corporation Information

Table 121. BDR Pharma Description and Major Businesses

Table 122. BDR Pharma Product Models, Descriptions and Specifications

Table 123. BDR Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. BDR Pharma Recent Developments

Table 125. Qilu Pharmaceutical Corporation Information

Table 126. Qilu Pharmaceutical Description and Major Businesses

Table 127. Qilu Pharmaceutical Product Models, Descriptions and Specifications

Table 128. Qilu Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Qilu Pharmaceutical Recent Developments

Table 130. Kelun Pharmaceutical Corporation Information

Table 131. Kelun Pharmaceutical Description and Major Businesses

Table 132. Kelun Pharmaceutical Product Models, Descriptions and Specifications

Table 133. Kelun Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Kelun Pharmaceutical Recent Developments

Table 135. Yichang Humanwell Pharmaceutical Corporation Information

Table 136. Yichang Humanwell Pharmaceutical Description and Major Businesses

Table 137. Yichang Humanwell Pharmaceutical Product Models, Descriptions and Specifications

Table 138. Yichang Humanwell Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 139. Yichang Humanwell Pharmaceutical Recent Developments

Table 140. Jiangsu Hansoh Pharmaceutical Corporation Information

Table 141. Jiangsu Hansoh Pharmaceutical Description and Major Businesses

Table 142. Jiangsu Hansoh Pharmaceutical Product Models, Descriptions and Specifications

Table 143. Jiangsu Hansoh Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 144. Jiangsu Hansoh Pharmaceutical Recent Developments

Table 145. PuraCap Pharmaceuticals Corporation Information

Table 146. PuraCap Pharmaceuticals Description and Major Businesses

Table 147. PuraCap Pharmaceuticals Product Models, Descriptions and Specifications

Table 148. PuraCap Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 149. PuraCap Pharmaceuticals Recent Developments

Table 150. Shenyang Hongqi Pharmaceutical Corporation Information

Table 151. Shenyang Hongqi Pharmaceutical Description and Major Businesses

Table 152. Shenyang Hongqi Pharmaceutical Product Models, Descriptions and Specifications

Table 153. Shenyang Hongqi Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 154. Shenyang Hongqi Pharmaceutical Recent Developments

Table 155. Key Raw Materials Distribution

Table 156. Raw Materials Key Suppliers

Table 157. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 158. Milestones in Production Technology Evolution

Table 159. Distributors List

Table 160. Market Trends and Market Evolution

Table 161. Market Drivers and Opportunities

Table 162. Market Challenges, Risks, and Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Enzalutamide Drugs Product Picture

Figure 2. Global Enzalutamide Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Tablets Product Picture

Figure 4. Capsules Product Picture

Figure 5. Global Enzalutamide Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Hospital and Clinic

Figure 7. Retail Pharmacies

Figure 8. Other

Figure 9. Enzalutamide Drugs Report Years Considered

Figure 10. Global Enzalutamide Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 12. Global Enzalutamide Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Enzalutamide Drugs Revenue Market Share by Region (2020-2031)

Figure 14. Global Enzalutamide Drugs Sales (2020-2031) & (K Units)

Figure 15. Global Enzalutamide Drugs Sales (CAGR) by Region (2020-2031) (K Units)

Figure 16. Global Enzalutamide Drugs Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers Enzalutamide Drugs Sales Volume Market Share in 2024

Figure 18. Global Enzalutamide Drugs Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Tablets Revenue Market Share by Manufacturer in 2024

Figure 21. Capsules Revenue Market Share by Manufacturer in 2024

Figure 22. Global Enzalutamide Drugs Sales Market Share by Type (2020-2031)

Figure 23. Global Enzalutamide Drugs Revenue Market Share by Type (2020-2031)

Figure 24. Global Enzalutamide Drugs Sales Market Share by Application (2020-2031)

Figure 25. Global Enzalutamide Drugs Revenue Market Share by Application (2020-2031)

Figure 26. North America Enzalutamide Drugs Sales YoY (2020-2031) & (K Units)

Figure 27. North America Enzalutamide Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 28. North America Top 5 Manufacturers Enzalutamide Drugs Sales Revenue (US$ Million) in 2024

Figure 29. North America Enzalutamide Drugs Sales Volume (K Units) by Type (2020- 2031)

Figure 30. North America Enzalutamide Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 31. North America Enzalutamide Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 32. North America Enzalutamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 33. US Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 34. Canada Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 35. Mexico Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 36. Europe Enzalutamide Drugs Sales YoY (2020-2031) & (K Units)

Figure 37. Europe Enzalutamide Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 38. Europe Top 5 Manufacturers Enzalutamide Drugs Sales Revenue (US$ Million) in 2024

Figure 39. Europe Enzalutamide Drugs Sales Volume (K Units) by Type (2020-2031)

Figure 40. Europe Enzalutamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 41. Europe Enzalutamide Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 42. Europe Enzalutamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. Germany Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 44. France Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 45. U.K. Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 46. Italy Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 47. Russia Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 48. Asia-Pacific Enzalutamide Drugs Sales YoY (2020-2031) & (K Units)

Figure 49. Asia-Pacific Enzalutamide Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Top 8 Manufacturers Enzalutamide Drugs Sales Revenue (US$ Million) in 2024

Figure 51. Asia-Pacific Enzalutamide Drugs Sales Volume (K Units) by Type (2020- 2031)

Figure 52. Asia-Pacific Enzalutamide Drugs Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 53. Asia-Pacific Enzalutamide Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 54. Asia-Pacific Enzalutamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Indonesia Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 56. Japan Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 57. South Korea Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 58. China Taiwan Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 59. India Enzalutamide Drugs Revenue (2020-2031) & (US$ Million)

Figure 60. Central and South America Enzalutamide Drugs Sales YoY (2020-2031) & (K Units)

Figure 61. Central and South America Enzalutamide Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Central and South America Top 5 Manufacturers Enzalutamide Drugs Sales Revenue (US$ Million) in 2024

Figure 63. Central and South America Enzalutamide Drugs Sales Volume (K Units) by Type (2021-2031)

Figure 64. Central and South America Enzalutamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 65. Central and South America Enzalutamide Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 66. Central and South America Enzalutamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Brazil Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 68. Argentina Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 69. Middle East, and Africa Enzalutamide Drugs Sales YoY (2020-2031) & (K Units)

Figure 70. Middle East and Africa Enzalutamide Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 71. Middle East and Africa Top 5 Manufacturers Enzalutamide Drugs Sales Revenue (US$ Million) in 2024

Figure 72. Middle East and Africa Enzalutamide Drugs Sales Volume (K Units) by Type (2021-2031)

Figure 73. South America Enzalutamide Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 74. Middle East and Africa Enzalutamide Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 75. Middle East and Africa Enzalutamide Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 76. GCC Countries Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 77. Turkey Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 78. Egypt Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 79. South Africa Enzalutamide Drugs Revenue (2020-2025) & (US$ Million)

Figure 80. Enzalutamide Drugs Industry Chain Mapping

Figure 81. Regional Enzalutamide Drugs Manufacturing Base Distribution (%)

Figure 82. Global Enzalutamide Drugs Production Market Share by Region (2020-2031)

Figure 83. Enzalutamide Drugs Production Process

Figure 84. Regional Enzalutamide Drugs Production Cost Structure

Figure 85. Channels of Distribution (Direct Vs Distribution)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions